Malta - English - Medicines Authority

pharmaceutical works polpharma sa 19 pelplinska steet, 83-200 starogard gdanski, poland - dutasteride, tamsulosin hydrochloride - hard capsule - tamsulosin hydrochloride 0.4 mg dutasteride 0.5 mg - urologicals

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - topiramate - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

almus pharmaceuticals ltd - amisulpride - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - topiramate - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - topiramate - oral tablet - 200mg

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - disodium etidronate 200mg - tablet - 200 mg - active: disodium etidronate 200mg excipient: magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified water

New Zealand - English - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide fumarate 11.2mg equivalent to 10 mg tenofovir alafenamide;   - film coated tablet - 200mg/10mg - active: emtricitabine 200mg         tenofovir alafenamide fumarate 11.2mg equivalent to 10 mg tenofovir alafenamide   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry grey 85f97517 - descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and adolescents aged 12 years and older with body weight at least 35 kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy. descovy is not for use in pre-exposure prophylaxis (prep)?.

New Zealand - English - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide fumarate 28mg equivalent to 25 mg tenofovir alafenamide;   - film coated tablet - 200mg/25mg - active: emtricitabine 200mg         tenofovir alafenamide fumarate 28mg equivalent to 25 mg tenofovir alafenamide   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 85f105057 - descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and adolescents aged 12 years and older with body weight at least 35 kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy. descovy is not for use in pre-exposure prophylaxis (prep)?.

New Zealand - English - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ;  ; rilpivirine hydrochloride 27.5mg equivalent to rilpivirine 25 mg;  ; tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg;   - film coated tablet - 200mg/25mg/25mg - active: emtricitabine 200mg         rilpivirine hydrochloride 27.5mg equivalent to rilpivirine 25 mg   tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg   excipient: croscarmellose sodium opadry ii grey 85f17636 lactose monohydrate magnesium stearate microcrystalline cellulose polysorbate 20 povidone - indicated as a complete regimen for the treatment of hiv-1 infection in adults and adolescents (12 years and older with a body weight at least 35 kg) with plasma hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of odefsey.

European Union - English - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimethyl fumarate - multiple sclerosis, relapsing-remitting - immunosuppressants - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.